Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.56 |
| ▸ | CA2 | P00918 | 16/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 9/20 | 0.56 |
| ▸ | CA12 | O43570 | 9/20 | 0.56 |
| ▸ | CA7 | P43166 | 9/20 | 0.56 |
| ▸ | CA9 | Q16790 | 8/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15648485 | 0.92 | CA1 (0.52) | CA1CA2CA13CA12CA7 | |
| SCHEMBL15646834 | 0.92 | CA1 (0.52) | CA1CA2CA13CA12CA7 | |
| SCHEMBL17091724 | 0.76 | CA1 (0.52) | CA1CA2CA13CA12CA7 | |
| SCHEMBL2777144 | 0.74 | PTGES2 (0.42) | CA1CA2CA13CA12CA7 | |
| SCHEMBL2779800 | 0.74 | CA1 (0.43) | CA1CA2CA13CA12CA7 | |
| SCHEMBL2776018 | 0.74 | CA2 (1.00) | CA1CA2CA13CA12CA7 | |
| SCHEMBL17091746 | 0.74 | PTPN7 (0.47) | CA1CA2KMT2APOLB | |
| SCHEMBL26976688 | 0.72 | CA1 (0.64) | CA1CA2CA13CA12CA7 | |
| SCHEMBL2932062 | 0.72 | CA1 (0.39) | CA1CA2CA13CA12CA7 | |
| SCHEMBL17091726 | 0.71 | CA1 (0.63) | CA1CA2CA13CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266900-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2015-09-24 | — | — | US | claimed |
| US-9725467-B2 | Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase | VILNIUS UNIVERSITY (LT) | 2017-08-08 | — | — | US | disclosed |
| US-20150266900-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2015-09-24 | — | — | US | disclosed |
| EP-2914583-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | Vilnius University (LT) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014062044-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | VILNIUS UNIVERSITY (LT) | 2014-04-24 | — | — | WO | disclosed |
| EP-2147915-B1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2010-09-15 | — | — | EP | disclosed |
| US-7741320-B2 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-06-22 | — | — | US | disclosed |
| EP-2147915-A1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2010-01-27 | — | — | EP | disclosed |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | US | disclosed |
| WO-2010004139-A1 | NEW CYCLOALKYLATED BENZOTHIADIAZINE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266900-A1 | FLUORINATED BENZENESULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE | CA9, CA7, CA2 | CA1 7/4885CA2 3/4885CA13 11/4885 |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | ACLY, HCAR1, GABRG1 | CA1 3557/4885CA2 1509/4885CA13 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.